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72 Poster Session Iexpressed as AUC and outcome. Methods: All children, trans-
planted between 2001–2006, receiving intravenous BU as part
of a myeloablative regimen, from whom AUC measurements
were available, were included. Patients were separated into five
percentiles based on total AUC. The association with the primary
endpoints EFS (event defined as dead, graft-failure or relapse)
and survival as well as the secondary endpoints (acute Graft-ver-
sus-Host Disease grade 2–4; aGvHD, and Veno-occlusive Dis-
ease: VOD) were tested using uni- and multivariate Cox
regression analysis. The lowest AUC group was used as index
group. Results: 102 patients were included (46 malignant indica-
tions; 56 non-malignant indications). Median age at transplantation
was 3.1 years (range 0.2 to 21 years). The overall EFS and survival
were 68% and 72% respectively. In multivariate analyses a total
AUC between 72,500–80,000mgh/l was associated with highest
EFS (85%, p 5 0.029, table). Other factors influencing EFS were
HLA-disparity and age at SCT. Similar associations were found
for survival. aGvHD occurred in 16% of patients and was most fre-
quently seen in the highest AUC group 35% (p 5 0.041, table).
VOD was noted more frequent in the higher AUC, but not signif-
icant (p 5 0.164). The once daily dosing versus 4-times daily did
not influence any of the results. Above an AUC of 72.500 mgh/l,
no graft-failure was note and only 2 relapses (11%) were note.
While under 72.500 mgh/l, 9 graft-failure and relapses were seen
(31%).
In conclusion a total AUC between 72,500–80,000 mgh/l is as-
sociated with highest EFS in malignants as well as in non-malignant
disease. Higher AUC was associated with more toxicity negatively
influencing EFS, while lower AUC was associated with more re-
lapse/graft failure. Once daily dosing might be a practical alterna-
tive to 4-times daily. Dosing of busulfan in children should be
targeted by therapeutic drug monitoring to a small therapeutic
range to improve EFS.
Multivariate analysis of primary and secondary endpoint: EFS en GvHD
EFS GvHDP HR CI-95% P OR CI-95%AUC 0–55.000 1 1AUC 55,000–65,000 0.320 0.60 0.22–1.64 0.920 0.86 0.05–15.8AUC 65,000–72,500 0.537 0.72 0.25–2.05 0.330 3.41 0.29–40.2AUC 72,500–80,000 0.029 0.20 0.05–0.85 0.177 5.58 0.46–67.7AUC 80,000–120,000 0.378 0.59 0.18–1.92 0.041 12.55 1.10–143Malign vs
non-malignant0.080 5.13 0.82–31.9HLA disparity 0.001 3.79 1.72–8.35 0.197 0.38 0.09–1.65Melphalan 0.541 1.71 0.31–9.43Sero-therapy 0.244 2.42 0.55–10.7Age 0.001 1.12 1.05–1.19195
INFLUENCE OF DONOR AGE ON RISK OF CHRONIC GVHD IN SEX-MIS-
MATCHED PEDIATRIC ALLOGENIC HEMATOPOIETIC STEM CELL TRANS-
PLANT
Friedrich-Medina, P.M.2, Duncan, C.N.1, Lehmann, L.E.1. 1 Dana
Farber Cancer Institute/Children’s Hospital Boston, Boston, MA; 2 Chil-
dren’s Hospital Boston, Boston, MA.
Background: Donor age, donor/recipient sex mismatch, and do-
nor parity are considered to be significant risk factors for the devel-
opment of acute and chronic graft versus host disease. Most reports
indicate that female donors into male (F-M) recipients confer the
greatest risk. Female donor alloimmunization to minor histocom-
patibility antigens encoded by the Y-chromosome is thought to de-
velop through sexual exposure and/or parity and at least partially
explain the increased risk of GVHD seen in F-M transplants. There
are no studies that evaluate this association when a young female
serves as donor. Methods: Data from 43 male to male (M-M) and
38 female to male (F-M) sibling donor hematopoietic transplants
performed at our institution from 1998–2006 was collected and an-
alyzed. Twenty three F-M transplants used female donors less or
equal to 12 years old. Age range and mean age for each group wasas follows: M-M (1–23 years, 11 years), F-M with donor less than
or equal to 12 years old (0.2–16 years, 7 years), and F-M with donor
over 12 years old (9–33 years, 15 years). The majority of patients in
both groups had hematologic malignancies, was fully matched, and
received Cyclosporine and Methotrexate as GVHD prophylaxis.
Outcomes between patients with female donors less or equal to
12 years old were compared to those of patients with female donors
more than 12 years old, using patients with M-M transplant as base-
line. Only patients with aGVHD grade II-IV were included in anal-
ysis. Patients with death in the first 100 days were not included in
the cGVHD analysis.Results:As reported from adult literature, in-
creased risk of chronic GVHD (RR5 3.3, 95%CI5 1.47–7.38, p5
0.006) was observed in F-M transplant from older female donor
when compared to M-M (RR5 1). However, no significant increase
in risk of acute or chronic GVHD (RR5 0.76, p5 0.5; RR5 0.93,
p 5 0.9) was observed when the subgroup including young female
donors was compared to M-M (RR 5 1). Furthermore, no signifi-
cant difference in relapse or transplant related mortality rates in
the first 100 days were observed. Conclusion: This data suggests
that the increased risk for chronic GVHD observed in adult sex-
mismatched allogenic transplants may be related to donor alloim-
munity and may not be present when a young female serves as
donor.
Effect of donor-recipient sex match on Grade II-IV aGVHD, cGVHD,
Disease Relapse and Death in first 100 days
RR 95% CI P valueaGVHD
M-M (n 5 43) 11 1 NA NA
F-M (all combined) 10 1.02 0.60–1.72 0.93
F-M\12 (n 5 23) 4 0.76 0.29–1.78 0.5
F-M .13 (n 5 15) 6 1.61 0.68–3.82 0.29cGVHD
M-M (n 5 40) 4 1 NA NA
F-M (all combined) 8 1.52 0.93–2.48 0.14
F-M\12 (n 5 22) 2 0.93 0.28–3.05 0.9
F-M .13 (n 5 14) 6 3.3 1.47–7.38 0.006Relapse
M-M (n 5 43) 12 1 NA NA
F-M\12 (n 5 23) 4 0.65 0.26–1.65 0.34
F-M .13 (n 5 15) 4 0.95 0.35–2.57 0.92Death
M-M (n 5 43) 3 1 NA NA
F-M\12 (n 5 23) 1 0.7 0.12–3.97 0.7
F-M .13 (n 5 15) 1 0.92 0.16–5.58 0.97NA5 Not applicable.196
ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) IN UNRELATED CORD
BLOOD TRANSPLANTATION (UCBT): SINGLE INSTITUTION EXPERI-
ENCE, JULY 1996 – JUNE 2007
Alsultan, A., Giller, R.H., Bathurst, J., Hild, E., Kissane, B., Gore, L.,
Foreman, N.K., Keating, A., Quinones, R.R. The Children’s Hospital
and the University of Colorado School of Medicine, Aurora, CO.
UCBT has been associated with a lower incidence of GVHD
when compared to unrelated transplant using adult donors. How-
ever, the characteristics (sites, time to onset, course, and tolerability)
of GVH following UCBT has not been as clearly elucidated. We re-
view GVH in 81 consecutive UCBT treated on a single therapeutic
trial with consistenet GVH prophylaxis. 13 patients were unevalu-
able based on death prior to UCB infusion (2), death prior to en-
graftment (7), or graft rejection (4). Thus, 68 patients were
evaluable for AGVHD (41 male, 27 female; median age 6.8 yr
(range, 0.3–24.4 yr); median weight 22 Kg (range, 5.35–82.9 Kg)).
Diagnoses included leukemia in 75% (63% ALL, 25% AML,
12% CML or JMML), MDS 3%, lymphoma 1%, metabolic disor-
ders 6%, immune/genetic disorders 9%, and aplastic anemia 6%.
Acute leukemia disease status at UCBT was CR1 24%, CR2
